Assembly Biosciences, Inc. Proceeds from Sale and Maturity of Marketable Securities
Assembly Biosciences, Inc. (ASMB) reported Proceeds from Sale and Maturity of Marketable Securities of $131.59 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-05.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2019-08-05
- Assembly Biosciences, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2019-06-30 was $70.14M, a 239.65% increase year-over-year.
- Assembly Biosciences, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2019-03-31 was $61.45M, a 413.35% increase year-over-year.
- Assembly Biosciences, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2018-12-31 was $6.96M, a 0.91% increase year-over-year.
- Assembly Biosciences, Inc. proceeds from sale and maturity of marketable securities for the quarter ending 2018-09-30 was $9.30M, a 44.78% increase year-over-year.
- Assembly Biosciences, Inc. proceeds from sale and maturity of marketable securities for fiscal 2018 was $48.88M, a 46.11% increase from fiscal 2017.
- Assembly Biosciences, Inc. proceeds from sale and maturity of marketable securities for fiscal 2017 was $33.46M, a 24.47% decline from fiscal 2016.
- Assembly Biosciences, Inc. proceeds from sale and maturity of marketable securities for fiscal 2016 was $44.29M, a 788.76% increase from fiscal 2015.
- Assembly Biosciences, Inc. proceeds from sale and maturity of marketable securities for fiscal 2015 was $4.98M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month | Proceeds from Sale and Maturity of Marketable Securities 12 month as first filed |
|---|---|---|---|---|---|
| 2019-06-30 | $70.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $131.59M 10-Q · filed 2019-08-05 | $138.55M derived: sum of 3 quarters · filed 2019-08-05 | $147.85M derived: sum of 4 quarters · filed 2019-08-05 | |
| 2019-03-31 | $61.45M 10-Q · filed 2019-05-09 | $68.42M derived: sum of 2 quarters · filed 2019-05-09 | $77.72M derived: sum of 3 quarters · filed 2019-05-09 | $98.37M derived: sum of 4 quarters · filed 2019-08-05 | |
| 2018-12-31 | $6.96M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $16.26M derived: sum of 2 quarters · filed 2019-02-28 | $36.91M derived: sum of 3 quarters · filed 2019-08-05 | $48.88M 10-K · filed 2019-02-28 | |
| 2018-09-30 | $9.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $29.95M derived: sum of 2 quarters · filed 2019-08-05 | $41.92M 10-Q · filed 2018-11-08 | $48.82M derived: sum of 4 quarters · filed 2019-08-05 | |
| 2018-06-30 | $20.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $32.62M 10-Q · filed 2019-08-05 | $39.52M derived: sum of 3 quarters · filed 2019-08-05 | $45.95M derived: sum of 4 quarters · filed 2019-08-05 | |
| 2018-03-31 | $11.97M 10-Q · filed 2019-05-09 | $18.87M derived: sum of 2 quarters · filed 2019-05-09 | $25.30M derived: sum of 3 quarters · filed 2019-05-09 | $38.77M derived: sum of 4 quarters · filed 2019-05-09 | |
| 2017-12-31 | $6.90M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $13.32M derived: sum of 2 quarters · filed 2019-02-28 | $26.80M derived: sum of 3 quarters · filed 2019-02-28 | $33.46M 10-K · filed 2019-02-28 | $33.46M 10-K · filed 2018-03-08 |
| 2017-09-30 | $6.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $19.90M derived: sum of 2 quarters · filed 2018-11-08 | $26.56M 10-Q · filed 2018-11-08 | $42.34M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-06-30 | $13.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $20.13M 10-Q · filed 2018-08-08 | $35.91M derived: sum of 3 quarters · filed 2019-02-28 | $47.26M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-03-31 | $6.66M 10-Q · filed 2018-05-07 | $22.44M derived: sum of 2 quarters · filed 2019-02-28 | $33.79M derived: sum of 3 quarters · filed 2019-02-28 | $40.50M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2016-12-31 | $15.78M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $27.13M derived: sum of 2 quarters · filed 2019-02-28 | $33.84M derived: sum of 3 quarters · filed 2019-02-28 | $44.29M 10-K · filed 2019-02-28 | $44.29M 10-K · filed 2017-03-02 |
| 2016-09-30 | $11.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $18.06M derived: sum of 2 quarters · filed 2017-11-01 | $28.52M 10-Q · filed 2017-11-01 | $30.80M derived: sum of 4 quarters · filed 2018-03-08 | |
| 2016-06-30 | $6.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $17.17M 10-Q · filed 2017-08-09 | $19.45M derived: sum of 3 quarters · filed 2018-03-08 | $22.15M derived: sum of 4 quarters · filed 2018-03-08 | |
| 2016-03-31 | $10.45M 10-Q · filed 2017-05-08 | $12.74M derived: sum of 2 quarters · filed 2018-03-08 | $15.44M derived: sum of 3 quarters · filed 2018-03-08 | $15.44M derived: sum of 4 quarters · filed 2018-03-08 | |
| 2015-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $4.98M derived: sum of 2 quarters · filed 2018-03-08 | $4.98M derived: sum of 3 quarters · filed 2018-03-08 | $4.98M 10-K · filed 2018-03-08 | |
| 2015-09-30 | $2.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $2.70M derived: sum of 2 quarters · filed 2016-11-09 | $2.70M 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $0.00 10-Q · filed 2016-08-09 | |||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-10 | ||||
| 2014-12-31 | $0.00 10-K · filed 2017-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |